Madrigal pharmaceuticals announces secondary offering of 1,200,000 shares of common stock

Conshohocken, pa., dec. 10, 2019 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl) (“madrigal” or the “company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases, today announced the commencement of an underwritten secondary offering of 1,200,000 shares of madrigal’s common stock by investment funds affiliated with bay city capital llc. in connection with the offering, the selling stockholders intend to grant the underwriter an option, exercisable for 30 days after the date of entry into the underwriting agreement related to the offering, to purchase up to 180,000 additional shares of common stock, at the public offering price, less underwriting discounts, from the selling stockholders. madrigal is not issuing or offering any shares of common stock in the offering and will not receive any proceeds from the sale of shares in the offering.
MDGL Ratings Summary
MDGL Quant Ranking